A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits.
The study, published in JAMA Health Forum and conducted by University of Chicago researchers, found that to meet common cost standards, the price of Novo Nordisk's Wegovy would need to drop by more than 80% to $127 per month, while the cost of Eli Lilly's Zepbound would need to be reduced by nearly one-third to $361 per month.
The researchers estimated the current average prices to be around $700 per month for Wegovy and $520 per month for Zepbound.
www.beckershospitalreview.com
The study, published in JAMA Health Forum and conducted by University of Chicago researchers, found that to meet common cost standards, the price of Novo Nordisk's Wegovy would need to drop by more than 80% to $127 per month, while the cost of Eli Lilly's Zepbound would need to be reduced by nearly one-third to $361 per month.
The researchers estimated the current average prices to be around $700 per month for Wegovy and $520 per month for Zepbound.
Zepbound, Wegovy fail to justify prices: Study - Becker's Hospital Review | Healthcare News & Analysis
A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and conducted by University of Chicago researchers, found that to meet common cost standards, the...
www.beckershospitalreview.com
